Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC

8075 Background: Fifty percent of NSCLC patients (pts) that develop a partial (PR) or complete (CR) response to gefitinib (G) or erlotinib (E) will develop a secondary EGFR T790M mutation as a mech...